Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 9
2004 4
2005 1
2006 2
2007 4
2008 3
2009 2
2010 2
2011 4
2012 5
2013 8
2014 9
2015 9
2016 12
2017 18
2018 18
2019 23
2020 39
2021 41
2022 28
2023 20
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Results by year

Filters applied: . Clear all
Page 1
CHARGE syndrome with both primary and secondary hypogonadism.
Yoshida Y, Ogawa S, Meguro S, Onagi A, Tanji R, Matsuoka K, Hoshi S, Hata J, Sato Y, Akaihata H, Kataoka M, Uemura M, Kojima Y. Yoshida Y, et al. Among authors: uemura m. IJU Case Rep. 2024 Jan 31;7(3):197-200. doi: 10.1002/iju5.12694. eCollection 2024 May. IJU Case Rep. 2024. PMID: 38686072 Free PMC article.
Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study.
Nagahara A, Uemura M, Sato M, Nakata W, Tsujihata M, Takao T, Matsumura S, Nishimura K, Takada S, Iwanishi T, Kobayashi Y, Ishizuya Y, Takada T, Okada K, Inoue H, Kato T, Hatano K, Kawashima A, Ujike T, Fujita K, Nonomura N. Nagahara A, et al. Among authors: uemura m. Jpn J Clin Oncol. 2024 Feb 1:hyae004. doi: 10.1093/jjco/hyae004. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 38305451
Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
Nishiyama N, Kita Y, Ito K, Kato M, Hatakeyama S, Matsushita Y, Naito S, Miyake M, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Nishiyama H, Kobayashi T, Kitamura H; Japan Urological Oncology Group. Nishiyama N, et al. Among authors: uemura m. Anticancer Res. 2023 Nov;43(11):5041-5050. doi: 10.21873/anticanres.16703. Anticancer Res. 2023. PMID: 37909969
Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment.
Minami K, Osawa T, Kojima T, Hara T, Eto M, Takeuchi A, Nakai Y, Ueda K, Ozawa M, Uemura M, Ohba K, Tamura K, Shindo T, Nakagomi H, Takahashi A, Anai S, Yokomizo A, Morizane S, Kimura T, Shimazui T, Miyauchi Y, Mitsuzuka K, Hara H, Yoshimura K, Shiina H, Ito YM, Murai S, Nishiyama H, Shinohara N, Kitamura H; Japanese Urological Oncology Group. Minami K, et al. Among authors: uemura m. Urol Oncol. 2023 Nov;41(11):458.e9-458.e19. doi: 10.1016/j.urolonc.2023.08.008. Epub 2023 Oct 3. Urol Oncol. 2023. PMID: 37798145
233 results